Incorporating added therapeutic benefit and domestic reference pricing into Medicare payment for expensive Part B drugs

10 September 2023 - A retrospective analysis using a 20% nationally representative sample of 2015 to 2019 traditional Medicare Part B ...

Read more →

Protecting Medicare’s discretion to say no to unproven therapies

8 September 2023 - Medicare, the largest health care payer in the nation, is also the single biggest source of revenue ...

Read more →

Review of cancer related surrogate outcomes used for PBAC decision-making

8 September 2023 - Surrogate outcome measures have an increasingly important role in cancer medicine research providing evidence to support ...

Read more →

Australia knocks back application for diabetes drug that could overshadow Ozempic

29 August 2023 - Australia has knocked back an application to subsidise the diabetes drug Mounjaro but the manufacturer still wants ...

Read more →

In the case of a devastating disease, the FDA weighs an experimental drug’s muddled data and a desperate need

14 August 2023 - Emma Albee knows the experimental drug she takes is not a cure. It won’t allow her ...

Read more →

PHARMAC’s funding model creating an ‘ethical dilemma’ - specialist

29 July 2023 - The New Zealand Breast Cancer Foundation is renewing calls for PHARMAC to fund Keytruda for the ...

Read more →

Statutory authority for Medicare coverage decisions - CMS is an independent federal agency

28 July 2023 - It is time for the public to recognize and strongly support the authority of the US Centers ...

Read more →

Pilot expert committee to support decision-making across the drug life cycle

8 June 2023 - CADTH, Canada’s drug and health technology agency, announces the creation and inaugural membership of a new ...

Read more →

A review of HTA guidelines on societal and novel value elements

25 May 2023 - Health technology assessment organisations vary in terms of how they conduct assessments.  ...

Read more →

Health Canada’s position on the CADTH guidance for reporting RWE to support decision-making

18 May 2023 - Canada’s CADTH collaborated with Health Canada and other stakeholders to develop the guidance for reporting real world ...

Read more →

Prioritising patients in negotiations over drug pricing

14 April 2023 - Overpaying for medicines diverts funds away from other treatments and services. ...

Read more →

Clarity around PHARMAC’s priority lists

30 March 2023 - PHARMAC released its first Clarity Report, containing the latest information about medicines, vaccines, and related products ...

Read more →

Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices.

10 March 2023 - By law, Medicare will have to take a medication’s efficacy and its research and development costs ...

Read more →

Our progress in the funding of medicines for rare disorders

3 March 2023 - PHARMAC will hear from people affected by rare disorders in its upcoming Rare Disorders Advisory Committee meeting ...

Read more →

Speeding up access to new medicines in Scotland: abbreviated process

8 February 2023 - A process brought in to streamline decision-making around access to new medicines in NHSScotland during the ...

Read more →